Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001045130 | SCV001208964 | uncertain significance | Developmental and epileptic encephalopathy, 25 | 2022-07-05 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 107 of the SLC13A5 protein (p.Lys107Arg). This variant is present in population databases (rs376995742, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with SLC13A5-related conditions. ClinVar contains an entry for this variant (Variation ID: 842675). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The arginine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV005278716 | SCV005941942 | uncertain significance | Inborn genetic diseases | 2025-01-30 | criteria provided, single submitter | clinical testing | The c.320A>G (p.K107R) alteration is located in exon 3 (coding exon 3) of the SLC13A5 gene. This alteration results from a A to G substitution at nucleotide position 320, causing the lysine (K) at amino acid position 107 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |